GlassScriptPhysician profile
Allison H Canavan
NPI 1790004059
$2,124.75
in general payments reported to CMS, 2019-2025
31 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.08 · 2020: $101 · 2021: $223 · 2022: $378 · 2023: $554 · 2024: $452 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $352.95 | 2021-2025 | |
| Gynesonics, INC. | $273.94 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Bayer Healthcare Pharmaceuticals INC. | $187.68 | 2020-2023 | |
| Intuitive Surgical, INC. | $132.18 | 2024 | |
| Abbvie INC. | $126.47 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $99.88 | 2019-2023 | Slynd |
| Hologic Sales and Service, LLC | $80.27 | 2024-2025 | Acessa Provu System, Fetal Fibronectin Enzyme Immunoassay |
| Organon LLC | $79.02 | 2021-2022 | |
| Viiv Healthcare Company | $68.21 | 2025 | Apretude |
| Millicent US INC | $61.12 | 2025 | Femlyv, Femring, Intrarosa |
| Meditrina | $57.76 | 2025 | |
| Myovant Sciences INC. | $53.10 | 2022 | |
| Baxter Healthcare | $52.74 | 2022-2023 | Tisseel |
| Astellas Pharma US INC | $48.85 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $47.85 | 2024 | Myfembree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $41.14 | 2021-2025 | Solosec, Phexx, Phexxi |
| Aspira Women'S Health INC | $34.51 | 2024 | Ova1 |
| Lupin INC. | $34.33 | 2019-2021 | |
| Allergan, INC. | $34.16 | 2019-2020 | |
| Pfizer INC. | $34.00 | 2023 | |
| Agile Therapeutics, INC. | $32.89 | 2023 | Twirla |
| Daiichi Sankyo INC. | $26.10 | 2024 | Injectafer |
| Shield Therapeutics INC | $23.85 | 2023 | Accrufer |
| Conmed Corporation | $23.33 | 2025 | Airseal |
| Coopersurgical, INC. | $19.48 | 2022 | |
| Becton, Dickinson and Company | $19.22 | 2023 | Bd Surepath Collection Vial |
| Sage Therapeutics, LLC | $17.14 | 2023 | |
| Exact Sciences Corporation | $15.82 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $15.78 | 2023 | Wegovy |
| Cranial Technologies, INC | $15.55 | 2020 | |
| Therapeuticsmd, INC. | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Canavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.